Management of thrombolysis-associated symptomatic intracerebral hemorrhage.

BACKGROUND Symptomatic intracerebral hemorrhage (sICH) is the most devastating complication of thrombolytic therapy for acute stroke. It is not clear whether patients with sICH continue to bleed after diagnosis, nor has the most appropriate treatment been determined. METHODS We performed a retrospective analysis of our prospectively collected Get With the Guidelines-Stroke database between April 1, 2003, and December 31, 2007. Radiologic images and all procoagulant agents used were reviewed. Multivariable logistic regression was performed to identify factors associated with in-hospital mortality. RESULTS Of 2362 patients with acute ischemic stroke during the study period, sICH occurred in 19 of the 311 patients (6.1%) who received intravenous tissue plasminogen activator and 2 of the 72 (2.8%) who received intra-arterial thrombolysis. In-hospital mortality was significantly higher in patients with sICH than in those without (15 of 20 [75.0]% vs 56 of 332 [16.9%], P < .001). Eleven of 20 patients (55.0%) received therapy for coagulopathy: 7 received fresh frozen plasma; 5, cryoprecipitate; 4, phytonadione (vitamin K(1)); 3, platelets; and 1, aminocaproic acid. Independent predictors of in-hospital mortality included sICH (odds ratio, 32.6; 95% confidence interval, 8.8-120.2), increasing National Institutes of Health Stroke Scale score (1.2; 1.1-1.2), older age (1.3; 1.0-1.7), and intra-arterial thrombolysis (2.9; 1.4-6.0). Treatment for coagulopathy was not associated with outcome. Continued bleeding (>33% increase in intracerebral hemorrhage volume) occurred in 4 of 10 patients with follow-up scans available (40.0%). CONCLUSIONS In many patients with sICH after thrombolysis, coagulopathy goes untreated. Our finding of continued bleeding after diagnosis in 40.0% of patients suggests a powerful opportunity for intervention. A multicenter registry to analyze management of thrombolysis-associated intracerebral hemorrhage and outcomes is warranted.

[1]  M. Scully,et al.  Thrombolytic therapy. , 1968, British medical bulletin.

[2]  K. Friedman,et al.  Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. , 1987, The Journal of clinical investigation.

[3]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[4]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[5]  J. Broderick,et al.  Early hemorrhage growth in patients with intracerebral hemorrhage. , 1997, Stroke.

[6]  R. Califf,et al.  Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. , 1998, Circulation.

[7]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[8]  G. Hankey,et al.  European Stroke Initiative Recommendations for Stroke Management , 2000, Cerebrovascular Diseases.

[9]  W. Hacke,et al.  Hemorrhagic Transformation of Ischemic Brain Tissue: Asymptomatic or Symptomatic? , 2001, Stroke.

[10]  C. Kessler,et al.  Consultative Hemostasis and Thrombosis , 2002 .

[11]  H. Diener,et al.  European Stroke Initiative Recommendations for Stroke Management – Update 2003 , 2003, Cerebrovascular Diseases.

[12]  K. Furie,et al.  Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke , 2004, Stroke.

[13]  S. Greenberg,et al.  Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage , 2004, Neurology.

[14]  J. Grotta,et al.  Treatment of acute intracerebral hemorrhage with ɛ-aminocaproic acid , 2004 .

[15]  J. Grotta,et al.  Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid: a pilot study. , 2004, Neurocritical care.

[16]  Peter Moyer,et al.  Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association’s Task Force on the Development of Stroke Systems , 2005, Circulation.

[17]  L. Lisabeth,et al.  Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. , 2005, Annals of emergency medicine.

[18]  Peter Moyer,et al.  Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association’s Task Force on the Development of Stroke Systems , 2005, Circulation.

[19]  S. Mayer,et al.  Safety and Feasibility of Recombinant Factor VIIa for Acute Intracerebral Hemorrhage , 2005, Stroke.

[20]  J. Grotta,et al.  Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. , 2005, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[21]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[22]  Mario Zuccarello,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.

[23]  F. Rasler.  Emergency treatment of hemorrhagic complications of thrombolysis. , 2007, Annals of emergency medicine.

[24]  Y. Fujii,et al.  Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control. , 2007, Journal of neurosurgery.

[25]  G. Schroth,et al.  Comparison of Intraarterial and Intravenous Thrombolysis for Ischemic Stroke With Hyperdense Middle Cerebral Artery Sign , 2008, Stroke.

[26]  Gary A. Ford,et al.  Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.

[27]  D. Rhoney,et al.  Hemostatic Therapy for the Treatment of Intracranial Hemorrhage , 2008, Pharmacotherapy.

[28]  S. Mayer,et al.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. , 2008, The New England journal of medicine.

[29]  L. Schwamm,et al.  Warfarin Reversal in Anticoagulant-Associated Intracerebral Hemorrhage , 2008, Neurocritical care.

[30]  Keith Muir,et al.  Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study , 2008, The Lancet.

[31]  Joseph P Broderick,et al.  National US Estimates of Recombinant Tissue Plasminogen Activator Use: ICD-9 Codes Substantially Underestimate , 2008, Stroke.

[32]  M. Budoff,et al.  National Institute of Neurological Disorders and Stroke , 2008 .

[33]  Li Liang,et al.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.

[34]  G. Moneta,et al.  Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke , 2009 .

[35]  Eric E. Smith,et al.  Off-Hour Admission and In-Hospital Stroke Case Fatality in the Get With The Guidelines-Stroke Program , 2009, Stroke.

[36]  K. Lee.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2010 .

[37]  K. Lee.  Off-Hour Admission and In-Hospital Stroke Case Fatality in the Get With The Guidelines-Stroke Program , 2010 .